Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 2,700 shares, a decline of 57.8% from the November 30th total of 6,400 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 20,000 shares, the days-to-cover ratio is currently 0.1 days.

Anebulo Pharmaceuticals Stock Up 4.9 %

ANEB stock traded up $0.08 during trading on Friday, reaching $1.70. The stock had a trading volume of 90,542 shares, compared to its average volume of 10,916. Anebulo Pharmaceuticals has a one year low of $0.80 and a one year high of $3.30. The company’s 50 day moving average is $1.57 and its two-hundred day moving average is $1.93. The company has a market capitalization of $44.09 million, a price-to-earnings ratio of -5.67 and a beta of -1.09.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its quarterly earnings data on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08. As a group, research analysts predict that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Benchmark restated a “speculative buy” rating and issued a $8.00 target price on shares of Anebulo Pharmaceuticals in a report on Tuesday, November 19th.

Insider Activity

In other Anebulo Pharmaceuticals news, Director Aron R. English bought 10,101,010 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $0.99 per share, for a total transaction of $9,999,999.90. Following the acquisition, the director now directly owns 15,467,300 shares of the company’s stock, valued at approximately $15,312,627. The trade was a 188.23 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 85.90% of the company’s stock.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.